Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
"We are delighted to be selected to give two oral presentations at the upcoming Keystone Symposium on Cancer Immunotherapy this year," said
Presentation & poster details |
|
Oral presentation date: |
|
Session title: |
Novel insights into T Cell Biology |
Lead author and presenter: |
Dr. |
Presentation & poster title: |
Unleashing Natural IL-18 Activity Using an Anti-IL-18BP Blocker Antibody Induces Potent Immune |
Poster date: |
|
Poster number: |
Poster #2042 |
|
|
|
|
Oral presentation date: |
|
Oral session title: |
Progress in Drugging the TIGIT and VISTA Pathways |
Lead author and presenter: |
Dr. Zoya Alteber, Ph.D., |
Presentation & poster title: |
PVRIG is Uniquely Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T Cells and |
Poster date: |
|
Poster number: |
Poster #1001 |
The abstracts are available on the publication section of
The presentations and posters will be made available on www.cgen.com, on the day of presentation.
About
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors.
Company contact:
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-selected-for-two-oral-presentations-at-the-keystone-symposium-on-cancer-immunotherapy-302085114.html
SOURCE